产品说明书
Mebendazole
 |
同义名 : | 甲苯达唑 ;NSC 184849;Vermox; Wormkuur; Vermin; Vermidil; Vermicol;R 17635;Mebenvet;Pantelmin;Telmin |
| CAS号 : | 31431-39-7 | |
| 货号 : | A162607 | |
| 分子式 : | C16H13N3O3 | |
| 纯度 : | 97% | |
| 分子量 : | 295.29 | |
| MDL号 : | MFCD00057872 | |
| 存储条件： |
粉末 Sealed in dry,Room Temperature 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 3 mg/mL(10.16 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Mebendazole is an antiparasitic which can bind nematode tubulin and cause inhibition of intestinal microtubule synthesis. It also inhibits Hh signaling, targeting SMO. Mebendazole was sufficient to reduce ShhN-induced expression of endogenous GLI1 and PTCH1 to basal levels at 0.1μM in the immortalized human retinal pigment epithelial cell line hTERT-RPE1. Similarly, there was partial reduction in GLI1 and PTCH1 transcripts at 0.1μM mebendazole and almost complete suppression at 1μM mebendazole, on the human medulloblastoma cell line DAOY. This inhibition of Hh signaling by Mebendazole led decrease of cell proliferation and survival, and increase apoptosis. Daily gavage of Mebendazole at dose of 50mg/kg for 38 days extended the median survival of DAOY orthotopic tumor xenograft mice. Mebendazole at 1μM decreased activation of SMO shown by the Gli-luc and Renilla reporter in NIH3T3 fibroblasts maintained in low-serum conditions for 48 hours. Mebendazole suppressed the formation of the primary cilium, a microtubule based organelle that functions as a signaling hub for Hh pathway activation. Combination of vismodegib and mebendazole resulted in additive Hh signaling inhibition[5]. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT00000314 | Cocaine-Related Disorders | Phase 2 | Completed | - | United States, New York ... 展开 >> VA Medical Center Brooklyn, New York, United States, 11209 收起 << |
| NCT00080444 | Vomiting | Phase 3 | Completed | - | - |
| NCT03472573 | Recurrent B Acute Lymphoblasti... 展开 >>c Leukemia Refractory B Acute Lymphoblastic Leukemia 收起 << | Phase 1 | Recruiting | November 2020 | United States, Pennsylvania ... 展开 >> Sidney Kimmel Cancer Center at Thomas Jefferson University Recruiting Philadelphia, Pennsylvania, United States, 19107 Contact: Margaret Kasner, MD 215-955-8874 margaret.kasner@jefferson.edu Principal Investigator: Margaret Kasner, MD 收起 << |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
3.39mL 0.68mL 0.34mL |
16.93mL 3.39mL 1.69mL |
33.87mL 6.77mL 3.39mL |
| 参考文献 |
|---|